1. Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease
- Author
-
Firoza Z. Lussier, Andrea Lessa Benedet, Nicholas J. Ashton, Paramita Saha-Chaudhuri, Yi-Ting Wang, Melissa Savard, Joseph Therriault, Tharick A. Pascoal, Philippe Huot, Cecile Tissot, Serge Gauthier, Jaime Fernandez Arias, Kaj Blennow, Etienne de Villers-Sidani, Henrik Zetterberg, Juan Lantero Rodriguez, Anniina Snellman, Thomas K. Karikari, Gleb Bezgin, Sulantha Mathotaarachchi, Pedro Rosa-Neto, and Mira Chamoun
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Aging ,Neurology ,Cognitive Neuroscience ,lcsh:RC346-429 ,lcsh:RC321-571 ,White matter ,03 medical and health sciences ,0302 clinical medicine ,Atrophy ,Cerebrospinal fluid ,Neuroimaging ,Alzheimer Disease ,Internal medicine ,medicine ,Humans ,Neurodegeneration ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,lcsh:Neurology. Diseases of the nervous system ,medicine.diagnostic_test ,business.industry ,Research ,Brain ,Magnetic resonance imaging ,Voxel-based morphometry ,medicine.disease ,Magnetic Resonance Imaging ,030104 developmental biology ,medicine.anatomical_structure ,Cross-Sectional Studies ,Positron-Emission Tomography ,Cardiology ,Plasma pTau181 ,Neurology (clinical) ,business ,Alzheimer’s disease ,030217 neurology & neurosurgery - Abstract
BackgroundTo investigate the association of plasma pTau181, assessed with a new immunoassay, with neurodegeneration of white matter and gray matter cross-sectionally and longitudinally, in aging and Alzheimer’s disease.MethodsObservational data was obtained from the Alzheimer’s Disease Neuroimaging Initiative, in which participants underwent plasma assessment and magnetic resonance imaging. Based on their clinical diagnosis, participants were classified as cognitively unimpaired and cognitively impaired. Linear regressions and linear mixed-effect models were used to test the cross-sectional and longitudinal associations between baseline plasma pTau181 and neurodegeneration using voxel-based morphometry.ResultsWe observed a negative correlation at baseline between plasma pTau181 and gray matter volume in cognitively unimpaired individuals. In cognitively impaired individuals, we observed a negative association between plasma pTau181 and both gray and white matter volume. In longitudinal analyses conducted in the cognitively unimpaired group, plasma pTau181 was negatively correlated with gray matter volume, starting 36 months after baseline assessments. Finally, in cognitively impaired individuals, plasma pTau181 concentrations were negatively correlated with both gray and white matter volume as early as 12 months after baseline, and neurodegeneration increased in an incremental manner until 48 months.ConclusionsHigher levels of plasma pTau181 correlate with neurodegeneration and predict further brain atrophy in aging and Alzheimer’s disease. Plasma pTau181 may be useful in predicting AD-related neurodegeneration, comparable to positron emission tomography or cerebrospinal fluid assessment with high specificity for AD neurodegeneration.
- Published
- 2020